The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of Vyjuvek for the ...

Krystal Biotech (KRYS) has received a positive recommendation from EU regulators for its drug Vyjuvek for the treatment of ...

Krystal said it is on track to launch Vyjuvek in Germany in the middle of the year and in France later in 2025.

Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's) announcement ...

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...

Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare ...

Krystal Biotech (KRYS) welcomed the European Medicines Agency’s announcement that its Committee for Medicinal Products for Human Use has issued ...

Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a royalty financing agreement with Castle Creek Biosciences, providing ...

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through ...

There are four main types of calcinosis cutis: dystrophic, metastatic, iatrogenic, and idiopathic. Calcinosis cutis secondary to acne vulgaris falls under the dystrophic category, where calcium ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...